Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated:  11/15/2017
University of Utah /ID# 130311
mi
from
Salt Lake City, UT
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated: 11/15/2017
University of Utah /ID# 130311
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated:  11/15/2017
Gastroenterology Associates of Tidewater /ID# 136332
mi
from
Chesapeake, VA
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated: 11/15/2017
Gastroenterology Associates of Tidewater /ID# 136332
mi
from
Chesapeake, VA
Click here to add this to my saved trials
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated:  11/15/2017
New River Valley Research Institute /ID# 129303
mi
from
Christiansburg, VA
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated: 11/15/2017
New River Valley Research Institute /ID# 129303
mi
from
Christiansburg, VA
Click here to add this to my saved trials
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated:  11/15/2017
Wisconsin Center for Advanced Research GI Associates, LLC /ID# 128008
mi
from
Milwaukee, WI
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated: 11/15/2017
Wisconsin Center for Advanced Research GI Associates, LLC /ID# 128008
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated:  11/15/2017
Medical College of Wisconsin at Froedtert Memorial Lutheran /ID# 128022
mi
from
Milwaukee, WI
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated: 11/15/2017
Medical College of Wisconsin at Froedtert Memorial Lutheran /ID# 128022
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated:  11/15/2017
Ordination Hainburg an der Donau, Altes Kloster /ID# 128086
mi
from
Hainburg/Donau,
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated: 11/15/2017
Ordination Hainburg an der Donau, Altes Kloster /ID# 128086
mi
from
Hainburg/Donau,
Click here to add this to my saved trials
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated:  11/15/2017
Ucsd /Id# 129304
mi
from
La Jolla, CA
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated: 11/15/2017
Ucsd /Id# 129304
mi
from
La Jolla, CA
Click here to add this to my saved trials
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated:  11/15/2017
Medical University of South Carolina Women's Health Research /ID# 137595
mi
from
Charleston, SC
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status: Enrolling
Updated: 11/15/2017
Medical University of South Carolina Women's Health Research /ID# 137595
mi
from
Charleston, SC
Click here to add this to my saved trials
Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment
Sensory Evaluation of a New Oral Nutrition Supplement in Patients at Risk for Mucositis
Status: Enrolling
Updated:  11/15/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment
Sensory Evaluation of a New Oral Nutrition Supplement in Patients at Risk for Mucositis
Status: Enrolling
Updated: 11/15/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Escondido, CA
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Escondido, CA
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
San Diego, CA
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Miami, FL
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Orlando, FL
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Atlanta, GA
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Oak Park, IL
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Oak Park, IL
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Lake Charles, LA
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Baltimore, MD
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Flowood, MS
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Flowood, MS
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Dayton, OH
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Mason, OH
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Mason, OH
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Austin, TX
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Dallas, TX
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Desoto, TX
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Desoto, TX
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Orem, UT
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Orem, UT
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Clovis, CA
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Clovis, CA
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis
Efficacy of Allergy Patch Testing in Directed Dietary Therapy of Eosinophilic Esophagitis: A Pilot Study
Status: Enrolling
Updated:  11/16/2017
The Mayo Clinic
mi
from
Rochester, MN
Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis
Efficacy of Allergy Patch Testing in Directed Dietary Therapy of Eosinophilic Esophagitis: A Pilot Study
Status: Enrolling
Updated: 11/16/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Birmingham, AL
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Dothan, AL
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Dothan, AL
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Mobile, AL
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
La Jolla, CA
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Torrance, CA
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Lone Tree, CO
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Lone Tree, CO
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Jacksonville, FL
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Miami, FL
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Naples, FL
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Naples, FL
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Atlanta, GA
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Arlington Heights, IL
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Urbana, IL
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Urbana, IL
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Hammond, LA
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Hammond, LA
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Chesterfield, MI
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Chesterfield, MI
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Rochester, MN
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Great Neck, NY
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Great Neck, NY
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
New York, NY
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Charlotte, NC
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Greenville, NC
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Greenville, NC
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Mentor, OH
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Mentor, OH
Click here to add this to my saved trials
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  11/17/2017
Clinical Research Facility
mi
from
Germantown, TN
AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 11/17/2017
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials